Publications
5677 Results
- Journal / Conference
- J Clin Oncol 40, 2022 (suppl 16; abstr 4522), poster 14; ASCO Annual Meeting (June 3-7, 2022, Chicago, IL)
- Year
- 2022
- Research Committee(s)
- Genitourinary
- Study Number(s)
- S1314
Association of DNA damage response (DDR) gene alterations (alts) and response to neoadjuvant cisplatin-based chemotherapy (chemo) in muscle-invasive bladder cancer (MIBC) patients (pts) enrolled onto SWOG S1314
- Journal / Conference
- J Clin Oncol 40, 2022 (suppl 16; abstr 1518), poster 112; ASCO Annual Meeting (June 3-7, 2022, Chicago, IL)
- Year
- 2022
- Research Committee(s)
- Cancer Care Delivery
- Study Number(s)
- S1415CD
A Pragmatic Cluster-Randomized Trial of a Standing Physician Order Entry Intervention for Colony Stimulating Factor use among Patients at Intermediate Risk for Febrile Neutropenia (SWOG S1415CD)
- Journal / Conference
- J Clin Oncol 40, 2022 (suppl 16; abstr 1525), poster 119; ASCO Annual Meeting (June 3-7, 2022, Chicago, IL)
- Year
- 2022
- Research Committee(s)
- Cancer Care Delivery
- Study Number(s)
- S1415CD
A pragmatic cluster-randomized trial of a computerized clinical decision support system to improve colony stimulating factor prescribing for cancer patients receiving myelosuppressive chemotherapy (SWOG S1415CD)
- Journal / Conference
- J Clin Oncol 40, 2022 (suppl 16; abstr 4506), abst 4506; ASCO Annual Meeting (June 3-7, 2022, Chicago, IL), oral
- Year
- 2022
- Research Committee(s)
- Genitourinary
- Study Number(s)
- S1314
Cell-free DNA methylation as a predictive biomarker of response to neoadjuvant chemotherapy for patients with muscle invasive bladder cancer in SWOG S1314
- Journal / Conference
- J Clin Oncol 40, 2022 (suppl 16; abstr TPS4608), poster 94a; ASCO Annual Meeting (June 3-7, 2022, Chicago, IL)
- Year
- 2022
- Research Committee(s)
- Genitourinary
- Study Number(s)
- S1937
A Phase III Randomized Trial of Eribulin (E) with or without Gemcitabine vs Standard of Care (SOC) for Metastatic Urothelial Carcinoma (UC) Refractory to or Ineligible for PD/PDL1 Antibody (Ab): SWOG S1937 (ClinicalTrials.gov NCT04579224)
- Journal / Conference
- J Clin Oncol 40, 2022 (suppl 16; abstr 11013), poster 204; ASCO Annual Meeting (June 3-7, 2022, Chicago, IL)
- Year
- 2022
Impact of Social Media on the Wellness of Pediatric and Adult Oncologists: A SWOG and COG survey
- Journal / Conference
- J Clin Oncol 40, 2022 (suppl 16; abstr 11049), poster 240; ASCO Annual Meeting (June 3-7, 2022, Chicago, IL)
- Year
- 2022
National impact of the COVID-19 pandemic on clinical trial staff attrition: Results of the SWOG Cancer Research Network survey of Oncology Research Professionals
- Journal / Conference
- J Clin Oncol 40, 2022 (suppl 16; abstr 5006), abst 5006; ASCO Annual Meeting (June 3-7, 2022, Chicago, IL), oral
- Year
- 2022
- Research Committee(s)
- Genitourinary
- Study Number(s)
- SWOG-9346
Assessing Intermediate Clinical Endpoints (ICE) as Potential Surrogates for Overall Survival (OS) in men with Metastatic Hormone Sensitive Prostate Cancer (mHSPC)
- Journal / Conference
- J Clin Oncol 40, 2022 (suppl 16; abstr 12023), poster 269; ASCO Annual Meeting (June 3-7, 2022, Chicago, IL)
- Year
- 2022
- Research Committee(s)
- Breast
- Study Number(s)
- S0221
Vitamin D Insufficiency as a Peripheral Neuropathy Risk Factor in White and Black Patients in SWOG 0221
- Journal / Conference
- J Clin Oncol 40, 2022 (suppl 16; abstr 594), poster 365; ASCO Annual Meeting (June 3-7, 2022, Chicago, IL)
- Year
- 2022
- Research Committee(s)
- Breast
- Study Number(s)
- S0800